Vol.18 No.3

Case Report

Use of etanercept in a patient with rheumatoid arthritis on hemodialysis

Authors

Yuko Sugioka1 , Kentaro Inui2 , Tatsuya Koike3

  • Department of Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan
  • Department of Orthopaedic Surgery and Rheumatology, Higashi-Sumiyoshi Morimoto Hospital, Osaka, Japan
  • Department of Rheumatosurgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan
Received:

5 November 2007

Accepted:

6 December 2007

Published online:

27 February 2008

Full Text

PDF　(member's only)

Abstract

Disease-modifying anti-rheumatic drugs (DMARDs) are typically used for the therapy of rheumatoid arthritis (RA), but most have some nephrotoxicity. In several clinical studies, etanercept had fewer adverse effects on renal function than other DMARDs. We report the case of a 64-year-old woman with RA and renal insufficiency on hemodialysis treated using etanercept therapy. This case suggests that etanercept therapy might be effective in the short term for such patients.

Key words

Etanercept - Hemodialysis - Rheumatoid arthritis